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SUMMARY
Glucose-stimulated insulin secretion from islet b
cells is mediated by KATP channels. However, the
role of non-KATP K
+ channels in insulin secretion is
largely unknown. Here, we show that a non-KATP K
+
channel, KCNH6, plays a key role in insulin secretion
and glucose hemostasis in humans and mice.
KCNH6 p.P235L heterozygous mutation co-sepa-
rated with diabetes in a four-generation pedigree.
Kcnh6 knockout (KO) or Kcnh6 p.P235L knockin
(KI) mice had a phenotype characterized by changing
from hypoglycemia with hyperinsulinemia to hyper-
glycemia with insulin deficiency. Islets from the
young KO mice had increased intracellular calcium
concentration and increased insulin secretion. How-
ever, islets from the adult KO mice not only had
increased intracellular calcium levels but also had
remarkable ER stress and apoptosis, associated
with loss of b cell mass and decreased insulin secre-
tion. Therefore, dysfunction of KCNH6 causes over-
stimulation of insulin secretion in the short term and
b cell failure in the long term.
INTRODUCTION
Glucose-stimulated insulin secretion (GSIS) from pancreatic islet
b cells is regulated by a series of electrogenic events. This elec-
trogenic mechanism is generally referred to as the ATP-sensitive
potassium (KATP) channel pathway. Metabolism of glucose leads
to an increase in the ATP/ADP ratio. This increase causes
closure of KATP channels, depolarization of the plasma mem-
brane, influx of calcium through voltage-gated calcium channels
(VDCCs), and exocytosis of insulin secretory granules. However,
during depolarization-induced action potentials, other K+ chan-
nelsmay responsible for action potential duration and frequency,
as well as for the repolarization of b cells (Braun et al., 2008;
Houamed et al., 2010).
Studies in vitro have shown evidence for non-KATP channel
stimulation of insulin secretion by glucose, especially a role for
voltage-dependent K+ (Kv) channels as modulators of insulin
secretion (Fe´lix-Martı´nez and Godı´nez-Ferna´ndez, 2014; Yang
et al., 2014). Reports have also shown that the ether-a-go-go-
related gene (ERG) channel is an active participant in the regula-
tion of b cell electrical activity and insulin secretion in the rat
pancreas and b cells in vitro (M€uhlbauer et al., 2007). Glucose-
dependent stimulation of insulin secretion from Kv channel
blockers has been reported in rodent islets and insulinoma cells
(MacDonald et al., 2001, 2002).
ERG-class channels are members of a larger family of Kv
channels. Three isoforms, KCNH2 (ERG), KCNH6 (ERG2),
and KCNH7 (ERG3), have been discovered (Shi et al., 1997).
Long QT syndrome, a dominant inherited channelopathy that
can result in sudden cardiac death, is caused by human
KCNH2 (Kv11.1) heterozygous mutations (Sanguinetti et al.,
1995). A report indicates that patients with long QT syndrome
due to loss-of-function mutation of KCNH6 have reactive high
insulin secretion associated with reactive hypoglycemia after
an oral glucose tolerance test (OGTT) (Hylte´n-Cavallius et al.,
2017).
It was reported that 3% of hyperglycemic adults diagnosed as
having type 2 diabetes (T2D) are affected by a multigenerational
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disease (Ludovico et al., 2015; Pezzilli et al., 2018). Here we first
show the evidence from patients with multigenerational diabetes
and twomousemodels supporting the pivotal role of both human
KCNH6 (Kv11.3) and mouse Kcnh6 in the regulation of insulin
secretion. We linked KCNH6 gene p.P235L mutation with dia-
betes in the pedigree. KCNH6 knockout (KO) and p.P235L
knockin (KI) mouse models mimicked the phenotype changing
from hyperinsulinemia to hypoinsulinemia and diabetes found
in the pedigree. This result suggests that KCNH6 plays a key
role in insulin secretion and glucose hemostasis in humans and
mice.
RESULTS
KCNH6 Mutation in a Four-Generation Pedigree
We have previously conducted a three-step programmed
method for the identification of yet-unknown gene mutations of
maturity-onset diabetes of the young (MODY-x) (Li et al.,
2016). In 2009, we identified a four-generation family with multi-
generational monogenic diabetes (Ludovico et al., 2015; Pezzilli
et al., 2018) from a mountain village in central China (Figure 1A).
We excluded mutations in all known high-frequency MODY-1,
MODY-2, and MODY-3 genes (Horikawa et al., 1997; Vionnet
et al., 1992; Yamagata et al., 1996a, 1996b) and KATP-related
MODY genes, including ABCC8 (MODY-12) (Bowman et al.,
2012) and KCNJ11 (MODY-13) (Bonnefond et al., 2012), in the
proband.
In 2010, we performed whole-exome sequencing on four
affected individuals (II-1, III-3, III-9, and III-14) who were diag-
nosed with diabetes at 30, 23, 30, and 35 years of age, respec-
tively (Figure 1A; Tables S1 and S2). After filtering (Table S3) and
being validated in all family members by Sanger sequencing,
only the heterozygous p.P235L mutation (Mut) in the KCNH6
gene (GenBank: NM_030779.2; c.704T >C) (Figure 1B) co-sepa-
ratedwith the diabetic phenotype. Biochemical parameters were
the same except that the Mut group had higher plasma glucose,
uric acid, and low-density lipoprotein (LDL) cholesterol levels
(Table S4).
KCNH6 Muts in Other Patients with Multigenerational
Diabetes
We sequenced the gene in a panel of 99 patients with early-onset
multigenerational diabetes (Thanabalasingham and Owen,
2011). We identified two families with heterozygous missense
Mut (p.R385G and p.R715W) that were not reported in the public
database dbSNP v.135 (Figures S1A–S1C; Table S5). KCNH6
p.P235L, p.R385G, and p.R715W muts were predicted to be
probably damaging protein function by PolyPhen2, with scores
of 0.990, 0.971, and 0.999, respectively (Figure S1D). Further-
more, these three Muts were predicted to be causing disease
by MutationTaster. This implies that KCNH6 Mut may not be a
rare finding in Chinese patients with early-onset multigenera-
tional diabetes.
From Hyper- to Hypoinsulinemia and Diabetes
In 2014, a baby (IV-1) with neonatal hypoglycemia was born to
patient III-3. This baby had blood glucose levels of 1.3 and
2.2 mmol/L before and after glucose treatment, respectively.
Figure 1. KCNH6 Mutations in a Four-Gen-
eration Pedigree with Multigenerational
Monogenic Diabetes
(A) Four-generation diabetes pedigree with
KCNH6 gene mutations. The proband is marked
by an arrow. Females are represented by circles,
and males are represented by squares. Subjects
marked with green, pink, and red are normal
glucose tolerance (NGT), impaired glucose toler-
ance (IGT), and diabetes mellitus (DM), respec-
tively. Patient ID, current age (age of diagnosis),
HbA1c levels, and current treatment are listed
below the circles or squares.;, childhood KCNH6
mutant subjects with hyperinsulinemia; :, a
newborn KCNH6 mutant baby with severe
neonatal hypoglycemia; OHA, oral hypoglycemic
agents; M, heterozygous KCNH6 p.P235L muta-
tion; W, wild-type; <, prediabetes defined by an
oral glucose tolerance test (OGTT).
(B and C) Family with monogenic diabetes had
KCNH6 heterozygous p.P235L mutations (P235L).
(B) Cartoon of one of the four subunits of KCNH6
channels. The N-terminal Per-Arnt-Sim (PAS)
domain preceded by a conserved sequence of
25–27 amino acids (PAS-cap) is in red. The ether-
a-go-go (EAG) is in orange. The C-linkers, the
C-terminal cyclic nucleotide binding homology
domain (CNBHD), and post-CNBHD domains are
in aquamarine, blue, and purple, respectively.
(C) DNA sequences of the KCNH6 wild-type (WT)
phenotype and P235L mutation.
Cell Reports 25, 3800–3810, December 26, 2018 3801
The newborn with neonatal hypoglycemia is a P235L genotype
of KCNH6, although no informed consent was obtained for
further blood tests. Furthermore, high blood insulin levels and
relatively low blood glucose levels were found in two P235L chil-
dren in the pedigree (Figure 2A). KCNH6 p.V532F heterozygous
Mut was previously reported to be a suspected cause of
neonatal hypoglycemia with hyperinsulinemia in an Italian family
(Proverbio et al., 2013).
In contrast, hypoinsulinemia was found in adult P235L family
members (Figure 2B). Insulin secretion decreased with age for
the P235L patients (Figure 2C), but not for wild-type pheno-
type (WT) family members (Figure 2D). Of the 13 adult Mut
members, all had glucose intolerance (6 with previously diag-
nosed diabetes, 3 with newly diagnosed diabetes, and 4 with
impaired glucose tolerance [IGT]). The P235L patients had
higher glucose levels (Figure 2E) and hemoglobin A1c
(HbA1c) levels (Figure 2F) and lower islet b cell function (Fig-
ures 2G–2I). However, of the WT adult members, 2 had IGT
and none had diabetes. Therefore, we speculate that KCNH6
p.P235L Mut causes monogenic diabetes characterized by
childhood hyperinsulinemia and adulthood hypoinsulinemia
and diabetes.
HbA1c
WTMut
0
2
4
6
8 *
A
III-1
III-2
0 1 2
0
50
100
150
Time (hr)
WT
Insulin
III-1
III-2
0 1 2
0
5
10
15
Time (hr)
WT
Glucose
0 1 2
0
50
100
150
Mut
WT
Time (hr)
Insulin
0 1 2
0
5
10
15
Mut
WT
Time (hr)
Glucose
0
100
200
AUC
**
0
10
20
30
AUC
FBG
WTMut
0
2
4
6
8
m
m
ol
/L
Fasting
Insulin
Wt Mut
0
2
4
6
8
HOMA-
WTMut
0
2
4
6
8
10
*
HOMA-IR
WTMut
0
1
2
AUC of GSIS
0 10 20 30 40 50 60
0
100
200
300
400
Age (yr)
AUC of GSIS
0 10 20 30 40 50 60
0
100
200
300
400
Age (yr)
A C
B
E F G H I
D
Figure 2. Clinical Parameters of the Family
Members
(A) Elevated glucose-stimulated insulin secretion
(left) and relatively low blood glucose levels (right)
during an oral glucose tolerance test (OGTT) in
childhood mutant family members.
(B) Decreased insulin secretion during OGTT for
adulthood mutant family members.
(C) Reduced area under the curve (AUC) of insulin
secretion with age for mutant family members.
(D) AUC of insulin secretion for WT family mem-
bers.
(E) Fasting blood glucose (FBG).
(F) Hemoglobin A1c (HbA1c).
(G) Fasting insulin (F-Ins).
(H) The Homeostasis Model Assessment (HOMA)
index of b cell function (HOMA-b).
(I) HOMA index of insulin resistance (HOMA-IR).
;, childhood KCNH6 mutant subjects with hy-
perinsulinemia; C, mutant adults without previ-
ously diagnosed diabetes (n = 7); B, WT adults
(n = 9). Values represent means ± SEM. *p < 0.05
versus WT. Significance values were calculated
using the Mann-Whitney U test.
Characteristics and Expression
Profiles of KCNH2
Loss-of-function Mut of the KCNH2 gene
can cause long QT syndrome (Hylte´n-
Cavallius et al., 2017). In this pedigree,
none of those with KCNH6 Mut suffered
from the syndrome when tested by elec-
trocardiogram (Figure S2), although an
obvious long QT interval is not always
seen for patients with this syndrome.
The protein sequence around the
P235L Mut is highly conserved not only
in the orthologs of the KCNH62 gene across species, including
rhesus, mouse, dog, chicken, and zebrafish (Figure S1E), but
also in the KCNH2-class family (KCNH2, KCNH6, and KCNH7)
(Figure S1F). The significant conservation of this position sug-
gests that the protein sequence including this Mut might play
critical roles in protein function.
Previously, a study with single-cell transcriptomic analysis of
human pancreatic islets indicated that KCNH6 mRNA was
expression mainly in islet a cells (Segerstolpe et al., 2016).
With real-time PCR assay, we found that KCNH6 was highly ex-
pressed in pancreas, heart, and kidney in humans, while KCNH2
was highly expressed in heart, lung, kidney, and pancreas in hu-
mans (Figure S3A). Double immunofluorescence staining with
antibodies against KCNH6 and insulin demonstrated that
KCNH6 protein was expressed in islet b cells in humans (Fig-
ure S3B) and mice (Figure S3C).
KCNH6 p.P235L Is a Dominant-Negative Mut
To examine the functional impact of KCNH6 p.P235L Mut on
the KCNH6 channels, a patch-clamp experiment was per-
formed. We constructed plasmids encoding human (wild-
type [WT]) and homozygous (m/m) KCNH6 p.P235L mutant,
3802 Cell Reports 25, 3800–3810, December 26, 2018
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Figure 3. Electrophysiology and Immunohistochemistry Analysis of the p.P235L Mutant KCNH6 Channel
(A–G) Voltage-clamp records of KCNH6 channels in KCNH6 null HEK293 cells transiently transfected with plasmids encoding null, WT, homozygous (m/m), and
heterozygous (W/m) mutant human KCNH6 (p.P235L).
(A) Representative western blot of KCNH6 protein.
(B) Representative KCNH6 current traces (50 mV) for HEK293 cells transfected with WT KCNH6 treated with E4031, a specific blocker of ERG channels.
(C) Representative current traces for HEK293 cells transfected with WT, W/m, m/m, and null KCNH6. The protocol of the depolarized voltage was from 60 to
50 mV for 3 s, and the repolarization voltage was 40 mV.
(D) Step current as measured from the triangles.
(E) Tail current as measured from the peak current.
(F) Normalized tail current as measured from the peak current that fitted with a Boltzmann function. Half-maximal activation (V1/2) and slope (k) factors for the
activation and inactivation data were calculated using a Boltzmann function: I = Imax/(1 + exp[(V1/2 X)/k]) for activation, where X is the test membrane potential.
(G) Time constants (t) for activation were calculated using a single exponential function: Y = Y0 + A 3 exp[(1/t) 3 t], where Y0 is the baseline current, A is the
amplitude of the exponential relaxation, and t is the time.
(legend continued on next page)
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which was then transfected into KCNH6 null HEK293 cells.
WT and m/m KCNH6 were transfected at a 1:1 ratio into
HEK293 cells as heterozygous (W/m). Similar levels of
KCNH6 protein expression (Figure 3A) were detected in
HEK293 cells transiently transfected with plasmids encoding
the WT, m/m, and W/m KCNH6. E4031, a blocker of KCNH2
channels, was used as a channel-specific control (Figure 3B).
Representative KCNH6 current traces for WT-, W/m-, and
m/m-transfected and WT-, W/m-, and m/m-untransfected
HEK293 cells recorded by patch clamp are shown (Figure 3C).
Compared with WT, m/m and W/m had lower step-current
density (Figure 3D) and tail-current density (Figure 3E). Other
electrophysiological properties, including steady-state inacti-
vation, deactivation curve, and recovery curve (Figure S4),
were similar among the three groups. The steady-state activa-
tion curve (Figure 3F) and time constant of activation of the
currents (Figure 3G) indicated that m/m and W/m had a
quicker activation property than WT.
Current density indicates overall channel function. Although
results of the gating kinetics indicated that KCNH6 p.P235L is
not a dysfunction Mut, overall function of the channel can be
affected by two factors: the gating kinetics and the amount of
channel on the plasma membrane or membrane targeting.
We then investigated membrane targeting and compared
the subcellular localization of the WT and the P235L channel
protein using immunocytochemistry and western blot anal-
ysis. The result indicated that while most WT KCNH6 was
distributed at the plasma membrane, the m/m and W/m
KCNH6 channels were clustered around the cell nucleus,
rather than on the cell membrane (Figure 3H). Western blot
analysis for subcellular fractions also showed that levels of
m/m and W/m KCNH6 expressed in the cell membrane were
significantly lower than those of WT KCNH6 in two indepen-
dent studies (Figure 3I). Thus, the WT/P235L (W/m) Mut-
induced dominant dysfunction of KCNH6 channels was attrib-
uted to impaired subcellular trafficking and localization of the
protein to the plasma membrane. Immunoprecipitation assay
revealed interactions between WT and m/m in two indepen-
dent studies (Figure 3J). These results indicate that dominant
dysfunction of W/m KCNH6 p.P235L Mut may be caused by
interactions between WT protein and p.P235L mutant protein,
because KCNH6 channels are tetramers of four identical
subunits arranged as a ring, with each ring contributing to
the wall of the transmembrane K+ pore (Haitin et al., 2013)
(Figure S1A).
Knockdown of Kcnh6 in INS-1 b Cells
Because KCNH6 p.P235L is a dysfunctional Mut, we propose
that downregulation of KCNH6 may influence insulin secretion.
We used short hairpin RNA (shRNA) to knockdown the mRNA
expression of Kcnh6 in the rodent INS-1 b cells (Figure S5A).
Kcnh6 knockdown enhanced glucose-induced elevation of the
intracellular calcium concentrations (Figure S5B). Consistently,
Kcnh6 knockdown significantly enhanced insulin secretion at a
high glucose concentration (Figure S5C).
Diabetes in Kcnh6 KO Mice
To test whether loss-of-function Mut of the KCNH6 channel
influences glucose homeostasis and insulin secretion found in
the family with KCNH6 Mut, we used our previously reported
TALEN-based method (Zu et al., 2013) to create Kcnh6 gene
KO mice (Figure 4A). A TALEN pair targeting exon 5 of the
Kcnh6 gene (around the p.P235L Mut) in C57BL/6 mice was de-
signed. The binding sites of left and right TALENs are specific for
target sequences in Kcnh6 that are unique within the KCNH2-
class genes (Figure S6). From western and immunohistochem-
istry experiments, KCNH6 was expressed in insulin-secreting
islet b cells in both humans and mice (Figure 4B; Figure S4B).
In neonatal KO mice, random plasma glucose levels were low
while the corresponding plasma insulin levels had a high trend
compared to age-matched WT controls (Figure 4C). However,
in 14-week-old young-adult KO mice, fasting plasma glucose
levels were high while the corresponding plasma insulin levels
were low compared to age-matched WT controls (Figure 4D).
At the same time, blood glucose levels on an intraperitoneal
glucose tolerance test (IPGTT) were significantly higher (Fig-
ure 4E), whereas the first- and second-phase insulin secretory
responses to glucose were reduced (Figure 4F). With consecu-
tive observations, the KO mice also showed significantly higher
blood glucose levels on IPGTT when compared with the WT
mice (Figure 4G). Insulin sensitivity of peripheral tissues in the
KO mice showed no obvious difference compared with the WT
mice at the age of 3 and 30 weeks, as evidenced by the insulin
tolerance test (ITT) (Figure 4H). The weight and food intake of
the KOmice had no significant change compared toWT (Figures
S7A–S7C). GLP-1 and glucagon secretion were also unchanged
at the age of 3 and 30 weeks (Figures S7D–S7G). Thus, Kcnh6
KO mice had a phenotype characterized by changing from hy-
perinsulinemia to hypoinsulinemia and diabetes.
Diabetes in Kcnh6 p.P235L KI Mice
We used a Cas9-based method targeting P235L of the C57BL/
6NmouseKcnh6 gene to createKcnh6 p.P235L KI mice (Figures
5A and 5B; Figure S8). In neonatal KI mice, random plasma
glucose levels were low while the corresponding plasma insulin
levels were relatively high compared to age-matched WT con-
trols (Figure 5C). Blood glucose levels on IPGTT were low at
the age of 3 weeks (Figure 5D). In adult KI mice, blood glucose
(H) Immunofluorescence staining for localization of WT, W/m, and m/m KCNH6 channels expressed in HEK293 cells. Nuclei were counterstained with DAPI,
which appears blue. KCNH6 is in red, and GFP is in green. All scale bars in white are 25 mm in length.
(I) Western blot analysis for KCNH6 protein from the total or from the plasma membrane (PM) fraction of HEK293 cells transfected with null, WT, W/m, and m/m
human KCNH6.
(J) HEK293 cells transfected with plasmids encoding FLAG-WT, Myc-Mut, and FLAG-WT/Myc-Mut human KCNH6 was immunoprecipitated using an anti-FLAG
affinity gel and immunoblotted with anti-FLAG (top panel) or anti-Myc antibodies (bottom panel).
Values represent means ±SEM. *p < 0.01, **p < 0.001 versusWT. Significance valueswere calculated using theMann-Whitney U test (n = 6, 4, and 8 forWT,W/m,
and m/m, respectively).
3804 Cell Reports 25, 3800–3810, December 26, 2018
levels on IPGTT were high (Figures 5E and 5G), while fasting in-
sulin levels and the first- and second-phase insulin secretory re-
sponses to glucose (Figure 5F) were reduced. The weight and
food intake of the KI mice were similar to those of the age-
matchedWTmice (Figure S9). Insulin sensitivity of peripheral tis-
sues in the KI mice showed no obvious difference in comparing
with the WT mice at the age of 3 and 30 weeks, as evidenced by
the ITT (Figure 5H).
Kv Current and Action Potential of Mouse Pancreatic b
Cells
We performed the electrophysiological experiment on the pri-
mary b cell from the KCNH6 KO and P235L KI mouse models.
The amplitude of action potential is approximately 30–40 mV in
magnitude from 55 mV, caused by high glucose stimulation
in mouse b cells. In patch clamping, the amplitude of action po-
tential is positively correlated with the injecting current stimulus
(Guo et al., 2014). The Kv current of b cells from the KO and KI
mice significantly decreased compared with that of the WT
mice (Figures 6A and 6B). The magnitude of action potential
was unaltered in the KO and KI and WT b cells. However, the
Figure 4. Mice with TALEN-Mediated Kcnh6
KO Mimic the Glucose Homeostasis of the
Pedigree
(A and B) TALEN-mediated Kcnh6 knockout (KO)
mice.
(A) Genotypes and DNA sequences of WT and
19 bp deletion frameshift KO.
(B) Western blot analysis of Kcnh6 protein in KO
and WT mouse islets.
(C) Random blood glucose (RBG) (WT, n = 8; KO,
n = 16) and plasma insulin (WT, n = 3; KO, n = 7) in
neonatal mice.
(D) Fasting blood glucose and insulin levels at
week 14 (WT, n = 9; KO, n = 11).
(E) Blood glucose levels and area under the curve
(AUC) during an intraperitoneal glucose tolerance
test (IPGTT) (3 g glucose/kg body weight [bw]) at
week 14 (WT, n = 9; KO, n = 11).
(F) First- and second-phase insulin secretory re-
sponses to glucose IPGTT (3 g glucose/kg bw) at
week 14 (WT, n = 9; KO, n = 11).
(G) Consecutive plasma glucose levels and area
under the curve (AUC) during IPGTT (2 g glucose/
kg bw) at weeks 3, 8, 12, 16, and 28 (WT, n = 7; KO,
n = 7).
(H) Consecutive plasma glucose levels and area
under the curve (AUC) during ITT (2 g glucose/kg
bw) at weeks 3 and 30 (WT, n = 7; KO, n = 7).
Values represent means ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001 versus WT. Significance values
were calculated using Student’s unpaired t test or
the Mann-Whitney U test if n < 9.
duration of action potential, especially
the repolarization time, was prolonged in
the KO and KI b cells (Figures 6C–6E).
These results indicate that the reduction
of the Kv current in the KO and KI b cells
may lead to the extension of action poten-
tial duration, which in turn can lead to an increase in cellular
excitability.
Mechanism from Hyper- to Hypoinsulin Secretion
Changes from hyperinsulin secretion to hypoinsulin secretion
were seen in islets from the young (3 weeks) and the middle-
age (30 weeks) KO mice. In the young mouse islet cells, a high
basal level of intracellular calcium was seen (Figure 7A). Consis-
tently, high insulin secretion was seen in response to high
glucose stimulation (Figure 7B). However, blunted intracellular
calcium elevation (Figure 7A) and dysfunction of insulin secretion
(Figure 7B) were seen in response to high glucose stimulation in
the middle-age mice. Insulin content was unchanged at 3 and
30 weeks (Figure 7C). Western blot showed that the KO mouse
islet had decreased proliferation, increased endoplasmic reticu-
lum (ER) stress, and apoptosis in the middle-age mice (Fig-
ure 7D). The islet b cell mass in the KO mice was decreased at
30 weeks. Immunocytochemistry analysis indicated a reduction
in insulin staining and an increase in glucagon-staining cells
within the core of the islet (Figure 7E). Immunochemistry also
showed an increased ER stress (Figure 7F) and apoptosis
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(Figure 7G) of islet cells from the KO mice at 30 weeks. Acridine
orange/propidium iodide (AO/PI) staining showed that dead islet
cells were elevated in the KO mice at 30 weeks (Figure 7H).
DISCUSSION
Our results indicate that hyperinsulin secretion and subsequent
hypoinsulin secretion caused by KCNH6 K+ channel dysfunc-
tion in humans and mice are a result of overstimulation of
insulin secretion. KCNH6 loss-of-function causes ultra-high
intracellular calcium concentration and super-high insulin secre-
tion in the short term. In the long term, this ultra-high calcium
concentration and overstimulation of insulin release may cause
ER stress, apoptosis, loss of b cell mass, and subsequent
decreased insulin secretions. Increased intracellular calcium
levels have toxic effects, leading to cell death (Gyengesi et al.,
2012). In addition, ER stress and apoptosis of islet cells may
be caused by chronic overstimulation of insulin secretion (Glaser
et al., 1999; Liang et al., 2014). Based on the calcium stress hy-
pothesis, overstimulation of insulin secretion appears to be a
double-edged sword. It may cause not only hyperinsulinemia
in the short term but also b cell failure in the long term (Efanova
et al., 1998). Therefore, KCNH6 Mut results in phenotype chang-
ing from hyper- to hypoinsulinemia and diabetes.
Consistent with this overstimulation and calcium stress hy-
pothesis, Muts in KATP channel genes (ABCC8 and KCNJ11)
Figure 5. Mice with Cas9-Mediated Kcnh6
p.P235L KI Exhibited the Diabetes 2 Pheno-
type
(A) Genotypes and DNA sequences of WT and
Kcnh6 p.P235L knockin (KI).
(B) Western blot analysis for Kcnh6 protein in WT
and KI mouse islets.
(C) Random blood glucose (RBG) (WT, n = 8; KI,
n = 6) and plasma insulin (WT, n = 3; KI, n = 5) in
neonatal KI and WT mice.
(D) Fasting insulin and glucose at week 28 (WT,
n = 6; KI, n = 8).
(E) Blood glucose levels and area under the curve
(AUC) during an intraperitoneal glucose tolerance
test (IPGTT) (3 g glucose/kg bw) at week 28 (WT,
n = 9; KI, n = 11).
(F) First- and second-phase insulin secretory re-
sponses to glucose IPGTT (3 g glucose/kg bw) at
week 28 (WT, n = 9; KI, n = 11).
(G) Consecutive plasma glucose levels and area
under the curve (AUC) during ITT (2 g glucose/kg
bw) at weeks 3, 8, and 24 (WT, n = 7; KI, n = 7).
(H) Consecutive plasma glucose levels and area
under the curve (AUC) during ITT (2 g glucose/kg
bw) at weeks 3 and 30 (WT, n = 8; KI, n = 8).
Values represent means ± SEM. *p < 0.05, **p <
0.01, ***p < 0.001 versus WT. Significance values
were calculated using Student’s unpaired t test or
the Mann-Whitney U test if n < 9.
can cause either hyperinsulinemia or
dysfunction of insulin secretion with dia-
betes (Kapoor et al., 2011). A study of a
large Finnish family described how a
dominant W/m p.E1506K Mut in ABCC8 caused congenital hy-
perinsulinemia in infancy, loss of insulin secretory capacity in
early adulthood, and diabetes in middle age (Huopio et al.,
2003). In another family, aW/mE1506KMut inABCC8was asso-
ciated with persistent hypoglycemia in the neonatal period and
diabetes in adulthood (Vieira et al., 2010). A Mut in KCNJ11
(p.Y12X) was known to cause human hyperinsulinemia, and an
interesting study showed that this Mut resulted in a glucose-
intolerant phenotype in mice (Hugill et al., 2010).
We know that MODY prevalence is low, and we should be
cautious to interpret KCNH6 p.P235L Mut as the cause of a
new MODY Mut. Of hyperglycemic adults diagnosed as having
T2D, 3% are affected by multigenerational monogenic diabetes
(Ludovico et al., 2015; Pezzilli et al., 2018). Usually, these pa-
tients present with the typical of metabolic abnormalities
observed in T2D. In these patients, age at diagnosis is older
than the age of patients with MODY but younger than the age
of patients with classic T2D (Ludovico et al., 2015; Pezzilli
et al., 2018).
We showed the staining of KCNH6 was not restricted to
plasma membrane. It appears that KCNH K+ channels should
be localized to plasma membrane. However, as previously re-
ported, the staining of KCNH-class channels was not restricted
to plasma membrane but rather was diffused throughout cytosol
(Li et al., 2014; Tanaka et al., 2014; Uhle´n et al., 2015). KCNH6 is
also expressed in a cells, and it is surprising that glucagon
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secretion is unaltered in this study. The reason may be that
although KCNH2 and KCNH6 are present in both a and b cells,
KCNH6 is relatively dominant in b cells, while KCNH2 is dominant
in a cells (Hardy et al., 2009). Therefore, KCNH6 current may not
be a dominant Kv current for glucagon secretion in a cells.
This study focused on finding the role of KCNH6 in insulin
secretion. The clinical data supporting KCNH6 Mut as a new
type of MODY are not strong and only give us a clue for further
investigation. Although many subtypes of Kv channels have
been detected in islet b cells (Fe´lix-Martı´nez and Godı´nez-Fer-
na´ndez, 2014; Yang et al., 2014), and some studies have inves-
tigated the contribution of Kv channels to membrane repolariza-
tion in b cells (Rorsman andBraun, 2013; Rosati et al., 2000), little
was known about which Kv channel is themain regulator respon-
sible for b cell repolarization and insulin secretion. This may due
to the lack of channel-blocking agents specific for each Kv chan-
nel. Whether the Kv-related KCNH6 channel is as a major
contributor to outward Kv currents for regulating insulin secre-
tion and a promising antidiabetic target needs to be studied
further.
Filling the knowledge gap on monogenic diabetes genes
would be extremely useful for etiological mechanisms, as well
as novel treatment approaches for diabetes. An example of
this usefulness relates to the KATP channel. This channel has
been exploited for the development of insulin secretagogues
for more than 60 years, including sulfonylureas and glinides
treating T2D and some types of monogenic diabetes (Pearson
et al., 2006).
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Figure 6. Kv Current and Action Potential of
Mouse Pancreatic b Cells
(A and B) Voltage-dependent K+ (Kv) channels of
mouse pancreatic b cells.
(A) Representative currents of WT, KO, and KI.
(B) Summary of the mean current density of Kv
channels at +70mV (KO, n = 5; KI, n = 7;WT, n = 3).
(C–E) Action potential of mouse pancreatic b cells.
(C) Action potential evoked by a 0.5 nA current.
(D) Action potential magnitude of KO (n = 3), KI
(n = 3), and WT (n = 4).
(E) 90% of action potential duration of KO (n = 3),
KI (n = 3), and WT (n = 6).
Values represent means ± SEM. *p < 0.05 versus
WT. Significance values were calculated using the
Mann-Whitney U test.
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Figure 7. Islets fromYoung andMiddle-AgeMicewithKcnh6KOExhibit Changes fromHyper- toHypoinsulin Secretionwith Concomitant ER
Stress and Apoptosis
(A–C) Islet cell parameters including glucose-stimulated intracellular calciummean level (A) (n = 3 b cells per group), glucose-stimulated insulin secretion (GSIS; B)
(n = 60 islets from 4 mice per group), and total pancreas insulin content (C) (n = 3–5 mice per group) from 3- or 30-week-old mice.
(legend continued on next page)
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id=776#keyword=INS-1&_pp=0_312
Experimental Models: Organisms/Strains
Mouse:C57BL/6N Vital River Laboratories http://www.vitalriver.com/proinfo.
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This paper N/A
Primer for TALEN target site; Forward:
CTGCTCTCTCCCTCTGTCCT
This paper N/A
Primer for TALEN target site; Reverse:
GGTATAGCCGCAGGTACCAC
This paper N/A
Primer for Cas9 target site; Forward:
TGCCTTTCATGACTGTGACA
This paper N/A
Primer for Cas9 target site; Reverse:
CGGTGCCTGCAGCTTGTACT
This paper N/A
The sequence of Cas9 designed for Kcnh6 point; Mut:
CTGCTAGGAAGACCGGTCTA TGG
This paper N/A
Recombinant DNA
Plasmid: GV314-EGFP GeneChem N/A
Plasmid: EGFP-KCNH6 This paper N/A
Plasmid: EGFP-KCNH6-Site Mut This paper N/A
shRNA of mouse Kcnh6: Origene Cat#: TF512772
Plasmid: pCS2-FokI Zu et al., 2013 N/A
Software and Algorithms
Prism 7 Graphpad https://www.graphpad.com
Version 11.4 MedCalc http://www.medcalc.com
Version 1 MutationTaster http://www.mutationtaster.org/
(Continued on next page)
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Dr. Jin-Kui
Yang (jkyang@ccmu.edu.cn).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Patients
Clinically suspected MODY: Screening criteria for MODY were based on the algorithm described previously (Thanabalasingham and
Owen, 2011). Those patients with a family history of diabetes for at least two generations, with an age of diagnosis between 14 and
30 years, and absence of insulin resistance were eligible.
This study was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University and performed accord-
ing to the principles of the Declaration of Helsinki II. We obtained written informed consent from each participant, and we got it from
the next of kin on the behalf of the minors/children taking part in this study.
Cell culture
Human embryonic kidney (HEK) 293 cells and INS-1 b-cells were cultured in a humidified atmosphere containing 5% CO2 provided
by Cell Resource Center, Chinese Academy of Medical Sciences (Beijing, China). HEK293 were cultured in Dulbecco’s modified Ea-
gle’smedium (DMEM) supplementedwith 10% fetal bovine serum (FBS) and 1%penicillin–streptomycin. INS-1 b-cells were cultured
in RPMI-1640 (GIBCO) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 50 mM 2-mercaptoethanol, 2 mM gluta-
mine, 10 mM HEPES, 1% penicillin–streptomycin.
Animal Model and Animal Care
Male C57BL/6Nmice were purchased from Vital River Laboratories (Beijing, China). Themice were kept at constant temperature and
humidity, with a 12 hr light and dark cycle, and fed a regular unrestricted diet. Both male and female mice were used in our exper-
iment, and we did not find any sex-based differences.
Mice with Kcnh6 KO were generated using our previously reported TALEN method (Zu et al., 2013). A TALEN pair targeting exon
5 of the C57BL/6N mice Erg2 gene was designed (Figure S6A). The binding sites of left and right TALENs’ specific for target se-
quences in Erg2, which are different from other genes (Figure S6B). Approximately 10 ng mRNAs synthesized using the
SP6 mMESSAGE mMACHINE Kit (Thermo) encoding each of the two TALENs were injected into the zygotes of C57BL/6N mice.
A 382bp genomic DNA fragment containing the target site was amplified using PCR.
We applied the Cas9 system targeting exon 5 of the C57BL/6N mice Erg2 gene to generate mice with point Muts in kcnh6. The
sequence of Cas9 is CTGCTAGGAAGACCGGTCTA TGG. mRNA encoding the Cas9 and the synthesized single-strand oligonucle-
otides donor sequences within P235L point Mut was injected into the zygotes of C57BL/6N mice. A 182 bp genomic DNA fragment
containing the target site from injected or control embryos was amplified using PCR.
Animal experiments followed the national ethical guidelines implemented by our institutional Animal Care and Use Committee and
were approved by the Ethical Review Committee at the Institute of Zoology, Capital Medical University, China.
METHOD DETAILS
Clinical and biochemical parameters
Medical histories including history of diabetes, diabetes duration and clinical parameters including body mass index (BMI),
blood pressure and waist circumference were recorded. Biochemical parameters including fasting plasma glucose (FPG), post-
prandial plasma glucose (PPG), total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), high-density lipoprotein
(HDL) cholesterol, creatinine (Cr), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by Uni-
cel DXC800 biochemistry analyzer (Beckman Coulter). Glycated hemoglobin A1c (HbA1c) was measured by a high-performance
liquid chromatography (HPLC) instrument, VARIANT II (Bio-rad). Insulin and C-peptide were determined using IMMUNLITE-2000
(Siemens). These biochemical measurements had been participated in the Chinese Ministry of Health Quality Assessment
Program.
Continued
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Oral glucose tolerance test (OGTT)
Blood samples were collected after an overnight fast for the determination of plasma glucose and HbA1c levels. After the fasting
blood specimen had been taken, a 75 g OGTT was performed between 08:00 and 10:00 hours (h). We took blood samples at 0,
0.5, 1, and 2h for measurement of concentrations of blood glucose, plasma insulin, and plasma C-peptide.
Classification of glucose homeostasis
FPG of R 7.0 mmol/l and/or OGTT-120h plasma glucose (2hPG) of R 11.1 mmol/l cases were classified as diabetes. Impaired
glucose tolerance (IGT) was defined on the basis of FPG < 7.0 mmol/l, 2hPG > 7.8 and < 11.1 mmol/l. Impaired fasting glucose
(IFG) was defined as FPG R 6.1 and < 7.0 mmol/l, 2hPG < 7.8 mmol/l. FPG of < 6.1 mmol/l and OGTT-120h plasma glucose
(2hPG) of < 11.1 mmol/l cases were classified as normal glucose tolerance (NGT).
Insulin resistance and b-cell function
To estimate insulin resistance, HOMA-IR index was calculated as the product of the fasting plasma insulin level (mU/ml) and the fast-
ing plasma glucose level (mmol/l), divided by 22.5. To estimate pancreatic b-cell function, HOMA-b index was calculated as the prod-
uct of the fasting plasma insulin level (mU/ml) and 20, divided by the fasting plasma glucose level minus 3.5.
Exome sequencing and bioinformatics analysis
Genomic DNA was isolated from peripheral blood leukocytes and sequenced by Sanger sequencing. Captured amplified product is
subjected to Hiseq 2000 platform and performed high-throughput sequencing as previously reported (Gao et al., 2014).
MutationTaster (http://www.mutationtaster.org/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) were used to predict
the possible impact of the Muts on protein function.
Real-time PCR
Total RNA was purified using an RNAprep pure Tissue Kit (Tiangen). The RNA samples were converted into cDNA with a FastQuant
RT Super Mix (Tiangen). The real-time qPCR was then performed on the LightCycler 480 Real-Time PCR System (Roche) using
SYBR Green I Master Mix reagent (Roche) with the primers.
Site-directed mutagenesis of human KCNH6 and HEK293 cell transfection
The humanKCNH6WT cDNAwas subcloned into theGV314-EGFP vector and P235LMutwas constructed by site-directedMut. The
transfection was divided into three groups according to the different plasmids: WT KCNH6 plasmid, P235L Mut plasmid and co-
expression of P235L and WT human KCNH6 (WT/Mut) plasmid in a 1:1 ratio. HEK293 cells were transiently transfected using Lip-
ofectamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol.
Immunohistochemistry
Human pancreatic tissues donated from the Pathology Department of Beijing Tongren Hospital, Capital Medical University. Human/
mouse pancreatic tissues and HEK293 infected with Wt, Mut and Wt/Mut KCNH6 channels were triple-washed with ice-cold PBS.
Cells or tissues were fixed by immersion in 4% paraformaldehyde for 4h at room temperature, followed by embedding in paraffin.
Heat-induced antigen retrieval then was performed on paraffin-embedded sections (5 mm) by utilizing a microwave in citrate buffer
at 99C for 5 min. Slides were incubated in normal serum at room temperature for 1h, followed by incubation with primary antibody
such as insulin antibody (1:100, Santa Cruz Biotechnology), glucagon antibody (1:5000, Sigma), insulin antibody (1:200, Cell
Signaling Technology) or KCNH6 antibody (1:200, Sigma) overnight at 4C. The sections were washed three times with PBS and
then were incubated with Alexa Fluor 555 donkey anti-goat-Cy3 (1:200, Santa Cruz Biotechnology), Alexa Fluor 555 donkey anti-
mouse IgG-CFL (diluted 1:200, Santa Cruz Biotechnology) or Alexa Fluor 488 goat anti-rabbit-Cy2 (1:200, Abcam) for 45 min at
room temperature. These sections were mounted with fluorescent mounting medium containing DAPI. Hematoxylin and Eosin
(HE) staining was used to observe the change of islets in morphology. For measurement of pancreatic b-cell area, a minimum of
20 fields per section were assessed using a laser scanning confocal microscope Leica TCSSP5. Captured images from immunohis-
tochemistry with insulin –positive area expect vacuoles were viewed under X200 magnifications.
Patch-Clamp experiment of KCNH6 in HEK293 cells and pancreas b-cells
HEK293 cells transiently expressing human KCNH6 were investigated using whole-cell patch clamping to measure the K+ current
throughWt, Mut andWt/Mut KCNH6 at room temperature. For the experimental current recording, cells were perfused with a Tyrode
solution containing (in mmol/l): NaCl 137.0, KCl 4.0, CaCl2 2.0, MgCl2 1.0, Glucose 10.0, HEPES 10.0, and the solution was adjusted
to pH 7.4 with NaOH. The pipette solution contains (in mmol/l) KCl 130.0, MgATP 5.0, MgCl2 1.0, EGTA 5.0, HEPES 10.0, and was
adjusted to pH 7.3 with KOH. Whole-cell configuration involved use of a glass pipette with tip resistance of 2.5–4.0 MU filled with the
internal pipette solution. The electrodes were constructed from borosilicate glass using a PB-7 micropipette puller (Narishige Instru-
ments). An EPC-10 patch-clamp amplifier was used with Pulse 8.8 software (HEKA). After cell membrane rupture, at least 5 min was
allowed for cell dialysis before any recording.
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For Kv channel current recording in mouse pancreas b-cells, the bath solution (in mM) was as follows: NaCl 125, KCl 10, MgCl2 2,
CaCl2 2, HEPES 10, D-glucose 5.6 with NaOH to pH 7.4. The pipettes were filled with solution (in mM): KCl 130, NaCl 10, MgCl2 2,
CaCl2 2, EGTA 10, HEPES 10, and ATP-Mg 1with KOH to pH 7.4. For action potential recording, cells were washedwith bath solution
containing (in mM): NaCl 130, KCl 5, MgCl2 1, CaCl2 2.5, HEPES 20, D-glucose 2.8 with NaOH to pH 7.4. The pipettes were filled with
solution (in mM): KCl 138, NaCl 10, MgCl2 1 and HEPES 10 with KOH to pH 7.4. Action potential is evoked by 0.5 nA current injection.
Co-immunoprecipitation
HEK293 cell lines were transfected with Flag-ERG2 (Wt) and/or Myc-ERG2 P23LMut. PcDNA3.1 plasmid was used as negative con-
trol. Cells were harvested in ice-cold solubilization buffer contained with 10mMHEPES, 50nMNaCl, 5mM EDTA, 1mM benzamidine,
0.5% Triton X-100. Then cells were incubated end-over-end at 4C for 1h to achieve solubilization. After centrifugation for 15min at
15000 g, supernatants were removed. The solubilizates were then incubated with 25 mL of anti-Flag M2 affinity gel (Sigma) with end-
over-end rotation at 4Covernight. After 6 washes with 1.0mL of ice-cold solubilization buffer, the immunoprecipitated proteins were
eluted from the beads via incubation with SDS-PAGE and visualized via western blot using anti-Flag (Sigma) or anti-Myc (Cell
Signaling Technology) antibodies.
Kcnh6 knockdown in INS-1 b-cells
INS-1 b-cells were transfected with shRNA of mouse Erg2 (OriGene) or scramble shRNA (as a negative control) using Lipofectamine
2000 (Invitrogen). The target sequences are listed as follows: 30-ACACGCAGATGCTGCGTGTCAAGGAGTTC-50.
Intraperitoneal Glucose tolerance test (IPGTT), intraperitoneal insulin releasing test (IPIRT) and Insulin tolerance test
(ITT)
IPGTT and IPIRT were performed in mice after they fasted overnight for 16 has described previously (Niu et al., 2008). At 0, 15, 30, 60,
and 120min after glucose (2g/kg body weight for IPGTT or 3g/kg body weight for IPIRT) injection. For IPGTT about 1 mL blood sample
was taken from the angular vein for testing blood glucose concentration using an automatic glucometer ACCU-CHEK Performa
(Roche). For IPIRT about 20 mL blood sample was taken from the angular vein for testing insulin concentrations during IPGTT. Insulin
concentration was assayed by an ELISA kit (Millipore). GLP-1 and glucagon were detected using ELISA kit (Millipore and R&D) ac-
cording to the manufacturer’s protocol.
ITT was performed in mice after fasted for 4h. At 0,15, 30, 60, 90, and 120 min after Human regular insulin (Eli Lilly) (0.1 U/ml in
saline; 0.75 U/kg body weight) injection, about 1 mL blood sample was taken from the angular vein for testing blood glucose concen-
tration using an automatic glucometer ACCU-CHEK Performa (Roche).
Isolation of mice pancreatic islets
Pancreatic islets were isolated from overnight-fasted mice by collagenase P (Roche) digestion method (Zmuda et al., 2011). Islets
viability was determined by AO/PI staining with living cells stained in green and dead cells stained in red. Isolated islets were incu-
bated in enzyme free cell dissociation solution (Millipore) for 5min and dispersed into a single cell for patch-clamp.
Glucose-stimulated insulin secretion (GSIS)
Islets were preincubated overnight in RPMI 1640medium. Stably transfected cells were seeded into 24-well plates and incubated for
48 h before GSIS studies were performed. To perform GSIS, groups of 20 islets or cells were washed with krebs-Ringer bicarbonate
buffer (KRBB) (129mmol/l NaCl, 4.8mmol/l KCl, 1.2mmol/l MgSO4, 1.2mmol/l KH2PO4, 2.5mmol/l CaCl2, 5mmol/l NaHCO3, 0.1%
BSA, and 10mmol/l HEPES, PH 7.4) and balanced for 30min, followed by incubation in KRBB containing 2.8mmol/l (basal concen-
tration) or 16.7mmol/l (stimulatory concentration) glucose for 1h at 37C. Insulin released into the supernatant and the insulin content
of the cells after acid/ethanol extraction (75% ethanol containing 1.5% (v/v) HCl) was measured using ELISA kits (Millipore).
The insulin secretion was normalized to protein content. Size-matched islets were placed in glass tubes containing HEPES Krebs
solution containing 0.5% BSA supplemented with glucose 5mM. Islets were centrifuge for 5min after adding acid ethanol for the in-
sulin measurements described above.
Western blot
For plasma membrane (PM) protein, isolation was used MinuteTM Plasma Membrane Protein Isolation Kit (Invent Biochnologies).
Approximately 20 mg sample proteins were loaded into 10% Mini-RROTEAN TGX SDS-Stain -Free Precast gels (Bio-Rad) and sub-
jected to electrophoresis. The separated proteins were transferred to polyvinylidene fluoridemembranes (Millipore) at 250mAper gel
for 2.5 h. After transfer, the membrane was blocked with blocking buffer and was incubated with a blocking buffer for 1.5h at room
temperature, followed by overnight incubation with 1:1000 dilution of the KCNH6 antibody (Sigma) at 4C. Other antibodies were
listed as follows: CHOP antibody (1:1000, Cell signaling Technology); GRP78 antibody (1:1000, Abcam); caspase 3 (1:500, Cell
signaling Technology) and b-actin (1:1000, Cell signaling Technology). After being washed with TBST for three times, the blots
were incubated for 1h with horseradish peroxidase (HRP)-labeled donkey-anti Rabbit IgG (1:2000, Santa Cruz Biotechnology). After
washing, the blots were detected by ECL chemiluminescence (Bio-Rad).
Cell Reports 25, 3800–3810.e1–e6, December 26, 2018 e5
b-Cell Mass Quantification
The method was described as before (Brouwers et al., 2014). The total surface area of insulin-positive cells (in pixels) was quantified
with Zeiss Axiovision of aware. The relative insulin surface area per section (total insulin area [pixels]/total pancreas area [pixels]) was
multiplied by the pancreas weight (mg) to obtain the b cell mass (mg).
Total pancreas insulin content
For determination of whole-pancreas insulin content, pancreas was immediately removed and placed in 4 mL of ice-cold acid
ethanol. After beingweighed, the samples weremanuallyminced and allowed to extract at20C for aminimumof 18h. After neutral-
ization with 10N NaOH, cellular debris was removed by centrifugation for 5 min at 1,000 g at 4C. The supernatant was removed and
diluted 1:10,000 for the insulin measurements described above. Total pancreas insulin content was calculated as pancreas weight
(mg) divided by the insulin level (mU/ml).
Intracellular Calcium Level Measurement
The [Ca2+]i in INS-1 b-cells or pancreatic b-cells were determined using Ca2+-sensitive fluorescent indicator dye Calcium Orange
(Thermo). Cells were loaded with 5 mmol/l Calcium Orange dissolved in HANKS buffer containing 0.005% Pluronic F-127 (Thermo)
at 37C in the dark for 20min. Cells were transferred in the KRBB buffer with 2.8mmol/l glucose for 5min at 37C. Fluorescence mea-
surements were carried out using an argon ion laser (excitation: 561 nm) using a Leica TCS SP confocal laser. Images were recorded
every 15 s for 5min. Baseline fluorescence (F0) was determined by averaging 20 images. Then cells were transferred in the KRBB
buffer with 16.7mmol/l glucose, images were recorded every 15 s for 15min. Fractional fluorescence (F/F0) indicates the changes
of intracellular calcium concentration. Image acquisitioned analysis was with an Ultra VIEW Vox confocal imaging system
(PerkinElmer).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data analysis
All statistical analyses were conducted with the software MedCalc version 11.4 or GraphPad Prism version 7. Data are presented as
mean ± SEM, and statistical Statistical details for individual experiments can be found in the figure legends.
Experiments performed in Kcnh6 KO mice (Figure 4) and Kcnh6 p.P235L KI mice (Figure 5) regarding the most important data,
glucose stimulated insulin secretion (GSIS) and intraperitoneal Glucose tolerance test (IPGTT) were carried out at least three times
with consistent results and one representative of each experiment is shown. *p < 0.05, **p < 0.01, ***p < 0.001.
DATA AND SOFTWARE AVAILABILITY
Data Resources
The accession numbers for the data of next generation sequencing on four affected individuals form the diabetes pedigree and
Sanger sequencing verification of KCNH6 gene Mut in the whole family and in a panel of 99 patients with multigenerational diabetes
reported in this paper are SRA: PRJNA506803.
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